Regentis Biomaterials Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.5M
- Price
- $2.06
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.62%
- Volume
- 46.0K
About
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Quick stats
Shares outstanding7.0M
Computed float2.4M
Float / shares34.2%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001912966
Websitehttps://www.regentis.co.il
AI Summary
AI-generated1/6
minorbullishoperations update
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Regentis Biomaterials received a Notice of Allowance from the Japan Patent Office for a patent covering its proprietary organic solvent-free manufacturing process for GelrinC.
The allowed patent offers a 5x increase in yield and strengthens IP protection in the Japanese cartilage repair market, which is estimated to reach $289 million by 2030.
GelrinC is preparing for commercial launch in Europe and has surpassed 50% enrollment in its pivotal U.S. FDA trial.